Emilio Perucca

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1774469/publications.pdf

Version: 2024-02-01

		8181	4774
285	31,462	76	169
papers	citations	h-index	g-index

324	324	324	19613
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia, 2014, 55, 475-482.	5.1	3,770
2	<scp>ILAE</scp> classification of the epilepsies: Position paper of the <scp>ILAE</scp> Commission for Classification and Terminology. Epilepsia, 2017, 58, 512-521.	5.1	3,464
3	Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51, 1069-1077.	5.1	3,400
4	Antiepileptic drugsâ€"best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 2008, 49, 1239-1276.	5.1	914
5	ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. Epilepsia, 2006, 47, 1094-1120.	5.1	782
6	Epilepsy: new advances. Lancet, The, 2015, 385, 884-898.	13.7	706
7	Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology, The, 2011, 10, 609-617.	10.2	654
8	Updated <scp>ILAE</scp> evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia, 2013, 54, 551-563.	5.1	599
9	Pharmacological and Therapeutic Properties of Valproate. CNS Drugs, 2002, 16, 695-714.	5.9	561
10	Clinically relevant drug interactions with antiepileptic drugs. British Journal of Clinical Pharmacology, 2006, 61, 246-255.	2.4	502
11	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology, The, 2003, 2, 347-356.	10.2	447
12	Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurology, The, 2009, 8, 82-93.	10.2	412
13	Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurology, The, 2003, 2, 473-481.	10.2	359
14	Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology, The, 2018, 17, 530-538.	10.2	348
15	Idiosyncratic Adverse Reactions to Antiepileptic Drugs. Epilepsia, 2007, 48, 1223-1244.	5.1	321
16	Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurology, The, 2007, 6, 793-804.	10.2	303
17	Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine. Clinical Pharmacokinetics, 1996, 31, 198-214.	3.5	284
18	International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1398-1442.	5.1	263

#	Article	IF	Citations
19	The pharmacological treatment of epilepsy in adults. Lancet Neurology, The, 2011, 10, 446-456.	10.2	259
20	Rufinamide: Clinical pharmacokinetics and concentrationâ€“response relationships in patients with epilepsy. Epilepsia, 2008, 49, 1123-1141.	5.1	244
21	ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1349-1397.	5.1	237
22	Determinants of health-related quality of life in pharmacoresistant epilepsy: Results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia, 2011, 52, 2181-2191.	5.1	227
23	Reversible Pseudoatrophy of the Brain and Mental Deterioration Associated with Valproate Treatment. Epilepsia, 1998, 39, 27-32.	5.1	219
24	Identification of new epilepsy treatments: Issues in preclinical methodology. Epilepsia, 2012, 53, 571-582.	5.1	219
25	Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disorders, 2014, 16, 409-431.	1.3	212
26	An International Multicenter Randomized Double-Blind Controlled Trial of Lamotrigine and Sustained-Release Carbamazepine in the Treatment of Newly Diagnosed Epilepsy in the Elderly. Epilepsia, 2007, 48, 1292-1302.	5.1	201
27	Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Research, 2013, 103, 2-30.	1.6	201
28	Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurology, The, 2016, 15, 210-218.	10.2	197
29	Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?. Journal of Epilepsy Research, 2017, 7, 61-76.	0.4	176
30	Pharmacologic Advantages of Antiepileptic Drug Monotherapy. Epilepsia, 1997, 38, S6.	5.1	175
31	Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurology, The, 2005, 4, 781-786.	10.2	168
32	Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Research, 2015, 111, 85-141.	1.6	161
33	Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drugâ€refractory epilepsy. Epilepsia, 2010, 51, 797-804.	5.1	160
34	The Clinical Pharmacokinetics of the Newer Antiepileptic Drugs. Clinical Pharmacokinetics, 1996, 31, 29-46.	3.5	156
35	A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG. Pharmacological Research, 1997, 35, 241-256.	7.1	152
36	The longâ€term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (Open Prospective Randomized Longâ€term Effectiveness) trial. Epilepsia, 2014, 55, 893-900.	5.1	149

#	Article	IF	Citations
37	ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1475-1499.	5.1	148
38	Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X). Epilepsy Research, 2010, 92, 89-124.	1.6	145
39	Epilepsy, seizures, physical exercise, and sports: A report from the <scp>ILAE</scp> Task Force on Sports and Epilepsy. Epilepsia, 2016, 57, 6-12.	5.1	145
40	The new generation of antiepileptic drugs: advantages and disadvantages. British Journal of Clinical Pharmacology, 1996, 42, 531-543.	2.4	144
41	Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and metaâ€analysis. Epilepsia, 2011, 52, 219-233.	5.1	140
42	Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Research, 2003, 57, 1-13.	1.6	136
43	Dose-dependent teratogenicity of valproate in mono- and polytherapy. Neurology, 2015, 85, 866-872.	1.1	136
44	Is There a Role for Therapeutic Drug Monitoring of New Anticonvulsants?. Clinical Pharmacokinetics, 2000, 38, 191-204.	3.5	135
45	An Introduction to Antiepileptic Drugs. Epilepsia, 2005, 46, 31-37.	5.1	135
46	30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurology, The, 2020, 19, 544-556.	10.2	134
47	Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs. Epilepsia, 2002, 43, 37-44.	5.1	126
48	Plasma Protein Binding of Drugs in Pregnancy. Clinical Pharmacokinetics, 1982, 7, 336-352.	3.5	119
49	Antiepileptic drug therapy: Does mechanism of action matter?. Epilepsy and Behavior, 2011, 21, 331-341.	1.7	117
50	Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology, 2020, 94, 1032-1037.	1.1	116
51	The new generation of antiepileptic drugs: advantages and disadvantages. British Journal of Clinical Pharmacology, 1996, 42, 531-543.	2.4	115
52	Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age. Clinical Pharmacokinetics, 2006, 45, 351-363.	3.5	113
53	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology, 2001, 153, 238-243.	3.1	112
54	Add-on Phenytoin Fails to Prevent Early Seizures after Surgery for Supratentorial Brain Tumors: A Randomized Controlled Study. Epilepsia, 2002, 43, 175-182.	5.1	112

#	Article	IF	Citations
55	Fetal Exposure to GABA-Acting Antiepileptic Drugs Generates Hippocampal and Cortical Dysplasias. Epilepsia, 2007, 48, 684-693.	5.1	109
56	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia, 2018, 59, 1811-1841.	5.1	108
57	Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Research, 2000, 41, 107-139.	1.6	107
58	Free Fraction of Valproic Acid: In Vitro Timeâ€Dependent Increase and Correlation with Free Fatty Acid Concentration in Human Plasma and Serum. Epilepsia, 1983, 24, 65-73.	5.1	105
59	Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs, 2019, 79, 1435-1454.	10.9	101
60	Teratogenicity of antiepileptic drugs. Current Opinion in Neurology, 2019, 32, 246-252.	3.6	101
61	Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age: An Update. Clinical Pharmacokinetics, 2013, 52, 627-645.	3.5	98
62	Navigating toward Fetal and Maternal Health: The Challenge of Treating Epilepsy in Pregnancy. Epilepsia, 2004, 45, 1171-1175.	5.1	97
63	Lacosamide. Nature Reviews Drug Discovery, 2008, 7, 973-974.	46.4	96
64	Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clinical Pharmacology and Therapeutics, 1994, 56, 471-476.	4.7	93
65	Identifying mutations in epilepsy genes: Impact on treatment selection. Epilepsy Research, 2019, 152, 18-30.	1.6	93
66	Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (<scp>EILAT XIII</scp>). Epilepsia, 2017, 58, 181-221.	5.1	92
67	The Clinical Pharmacokinetics of the New Antiepileptic Drugs. Epilepsia, 1999, 40, S7-S13.	5.1	90
68	Pharmacoresistance in Epilepsy. CNS Drugs, 1998, 10, 171-179.	5.9	87
69	What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NSâ€1209, and topiramate. Epilepsia, 2009, 50, 49-50.	5.1	86
70	Diurnal Fluctuations in Free and Total Steadyâ€State Plasma Levels of Carbamazepine and Correlation with Intermittent Side Effects. Epilepsia, 1984, 25, 476-481.	5.1	85
71	Antiepileptic drugs and intrauterine death. Neurology, 2015, 85, 580-588.	1.1	84
72	Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1333-1348.	5.1	84

#	Article	IF	Citations
73	Pharmacokinetic Interactions with Antiepileptic Drugs. Clinical Pharmacokinetics, 1982, 7, 57-84.	3.5	83
74	Epilepsy priorities in Europe: A report of the <scp>ILAE</scp>â€<scp>IBE</scp> Epilepsy Advocacy Europe Task Force. Epilepsia, 2015, 56, 1687-1695.	5.1	81
75	Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs, 2020, 34, 795-800.	5.9	81
76	International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1443-1474.	5.1	81
77	Harnessing the Clinical Potential of Antiepileptic Drug Therapy. CNS Drugs, 2001, 15, 609-621.	5.9	78
78	Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia, 2013, 54, 97-104.	5.1	77
79	Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs. Epilepsia, 2006, 47, 16-20.	5.1	75
80	Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an openâ€label extension of phase <scp>III</scp> randomized trials: Study 307. Epilepsia, 2018, 59, 866-876.	5.1	74
81	Lacosamide. CNS Drugs, 2009, 23, 555-568.	5.9	72
82	Clinical Pharmacokinetics of Fluvoxamine. Clinical Pharmacokinetics, 1994, 27, 175-190.	3.5	69
83	Overtreatment in Epilepsy. CNS Drugs, 2005, 19, 897-908.	5.9	69
84	Declining malformation rates with changed antiepileptic drug prescribing. Neurology, 2019, 93, e831-e840.	1.1	69
85	Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clinical Pharmacology and Therapeutics, 1999, 66, 547-553.	4.7	68
86	Challenges in the clinical development of new antiepileptic drugs. Pharmacological Research, 2016, 103, 95-104.	7.1	68
87	Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials. Epilepsy Research, 2005, 64, 1-11.	1.6	67
88	A multicenter, randomized, placeboâ€controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia, 2011, 52, 802-809.	5.1	67
89	Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Research, 1999, 33, 247-262.	1.6	65
90	Pharmacokinetic and Metabolic Investigation of Topiramate Disposition in Healthy Subjects in the Absence and in the Presence of Enzyme Induction by Carbamazepine. Epilepsia, 2005, 46, 378-384.	5.1	65

#	Article	IF	Citations
91	Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from <scp>EURAP</scp>. Epilepsia, 2016, 57, e173-7.	5.1	65
92	Novel Medications for Epilepsy. Drugs, 2011, 71, 2151-2178.	10.9	60
93	Topiramate Pharmacokinetics in Children and Adults with Epilepsy. Clinical Pharmacokinetics, 2005, 44, 407-416.	3.5	59
94	Increased Apparent Oral Clearance of Valproic Acid during Intake of Combined Contraceptive Steroids in Women with Epilepsy. Epilepsia, 2006, 47, 1569-1572.	5.1	59
95	Serum Carbamazepine Concentrations in Elderly Patients: A Case-matched Pharmacokinetic Evaluation Based on Therapeutic Drug Monitoring Data. Epilepsia, 2003, 44, 923-929.	5.1	57
96	Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. , 1987, 33, 139-144.		56
97	The Management of Epilepsy in the 1990s. Drugs, 1995, 49, 680-694.	10.9	56
98	Overtreatment in epilepsy: adverse consequences and mechanisms. Epilepsy Research, 2002, 52, 25-33.	1.6	55
99	Cardiac function and antiepileptic drug treatment in the elderly: A comparison between lamotrigine and sustainedâ€•release carbamazepine. Epilepsia, 2009, 50, 1841-1849.	5.1	55
100	Marketed New Antiepileptic Drugs: Are They Better Than Old-Generation Agents?. Therapeutic Drug Monitoring, 2002, 24, 74-80.	2.0	54
101	The current state of epilepsy guidelines: A systematic review. Epilepsia, 2016, 57, 13-23.	5.1	54
102	From global campaign to global commitment: The World Health Assembly's Resolution on epilepsy. Epilepsia, 2015, 56, 1651-1657.	5.1	53
103	The New Antiepileptic Drugs Pharmacological and Clinical Aspects. Current Pharmaceutical Design, 2000, 6, 839-860.	1.9	50
104	Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Research, 2010, 91, 273-282.	1.6	50
105	A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia, 2011, 52, e40-e44.	5.1	50
106	Epilepsy care during the COVIDâ€•19 pandemic. Epilepsia, 2021, 62, 2322-2332.	5.1	48
107	Drug metabolism in pregnancy, infancy and childhood. , 1987, 34, 129-143.		47
108	Antiepileptic drug selection for people with HIV/AIDS: Evidenceâ€•based guidelines from the ILAE and AAN. Epilepsia, 2012, 53, 207-214.	5.1	47

#	Article	IF	Citations
109	Plasma Protein Binding of Phenytoin in Health and Disease. Therapeutic Drug Monitoring, 1980, 2, 331-344.	2.0	46
110	Antiepileptic drugs and brain maturation: Fetal exposure to lamotrigine generates cortical malformations in rats. Epilepsy Research, 2008, 78, 131-139.	1.6	45
111	Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia, 2020, 61, 2365-2385.	5.1	45
112	A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy. Epilepsia, 2015, 56, 1162-1173.	5.1	44
113	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia, 2018, 59, 1842-1866.	5.1	44
114	Extended-Release Formulations of Antiepileptic Drugs: Rationale and Comparative Value. Epilepsy Currents, 2009, 9, 153-157.	0.8	43
115	Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology, 2021, 185, 108442.	4.1	43
116	CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1269-1279.	3.3	42
117	Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia, 2020, 61, 1082-1089.	5.1	42
118	Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy*. Clinical Pharmacology and Therapeutics, 1997, 61, 442-449.	4.7	41
119	Influence of Dosage, Age, and Co-medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response. Therapeutic Drug Monitoring, 2003, 25, 700-708.	2.0	41
120	The Management of Refractory Idiopathic Epilepsies. Epilepsia, 2001, 42, 31-35.	5.1	38
121	Quantitative comparison of barbiturates in essential hand and head tremor. Movement Disorders, 1991, 6, 65-68.	3.9	37
122	Pharmacokinetic Profile of Topiramate in Comparison with Other New Antiepileptic Drugs. Epilepsia, 1996, 37, S8-S13.	5.1	36
123	Is a separate monotherapy indication warranted for antiepileptic drugs?. Lancet Neurology, The, 2015, 14, 1229-1240.	10.2	36
124	Pharmacokinetic Variability of New Antiepileptic Drugs at Different Ages. Therapeutic Drug Monitoring, 2005, 27, 714-717.	2.0	35
125	Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. Epilepsia, 2010, 51, 921-925.	5.1	35
126	Gender issues in antiepileptic drug treatment. Neurobiology of Disease, 2014, 72, 217-223.	4.4	35

#	Article	IF	Citations
127	Drug Interactions with Phenytoin. Drugs, 1981, 21, 120-137.	10.9	34
128	Designing Clinical Trials to Assess Antiepileptic Drugs as Monotherapy. CNS Drugs, 2008, 22, 917-938.	5.9	34
129	What clinical trial designs have been used to test antiepileptic drugs and do we need to change them?[*]. Epileptic Disorders, 2012, 14, 124-131.	1.3	34
130	Development and validation of an HPLCâ€“UV detection assay for the determination of rufinamide in human plasma and saliva. Analytical and Bioanalytical Chemistry, 2011, 401, 1013-1021.	3.7	33
131	The pharmacogenomics of epilepsy. Expert Review of Neurotherapeutics, 2015, 15, 1161-1170.	2.8	33
132	A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia, 2020, 61, 1668-1677.	5.1	32
133	FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. Epilepsia Open, 2021, 6, 45-48.	2.4	32
134	Single-Dose Pharmacokinetics of Lamotrigine in Children: Influence of Age and Antiepileptic Comedication. Therapeutic Drug Monitoring, 2001, 23, 217-222.	2.0	31
135	Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Research, 2004, 59, 155-165.	1.6	31
136	Italian Consensus Conference on Epilepsy and Pregnancy, Labor and Puerperium. Epilepsia, 2009, 50, 7-23.	5.1	31
137	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clinical Pharmacokinetics, 2020, 59, 1493-1500.	3.5	31
138	Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. Expert Review of Neurotherapeutics, 2013, 13, 615-625.	2.8	30
139	The pharmacological treatment of epilepsy: recent advances and future perspectives. Acta Epileptologica, 2021, 3, .	0.9	30
140	Interpretation of Drug Levels in Acute and Chronic Disease States. Clinical Pharmacokinetics, 1985, 10, 498-513.	3.5	29
141	Free Concentration of Carbamazepine and Carbamazepine-10,11-Epoxide in Children and Adults. Clinical Pharmacokinetics, 1985, 10, 524-531.	3.5	29
142	Plasma Gabapentin Concentrations in Children With Epilepsy: Influence of Age, Relationship With Dosage, and Preliminary Observations on Correlation With Clinical Response. Therapeutic Drug Monitoring, 2003, 25, 54-60.	2.0	29
143	Pregabalin for the management of partial epilepsy. Neuropsychiatric Disease and Treatment, 2008, 4, 1211.	2.2	29
144	From clinical trials of antiepileptic drugs to treatment. Epilepsia Open, 2018, 3, 220-230.	2.4	29

#	Article	IF	Citations
145	Changes in Lamotrigine Pharmacokinetics during Pregnancy and the Puerperium. Therapeutic Drug Monitoring, 2008, 30, 544-547.	2.0	29
146	The Pharmacology of New Antiepileptic Drugs. CNS Drugs, 2011, 25, 907-912.	5.9	28
147	Novel therapies for epilepsy in the pipeline. Epilepsy and Behavior, 2019, 97, 282-290.	1.7	28
148	Low risk pragmatic trials do not always require participantsâ€™ informed consent. BMJ: British Medical Journal, 2019, 364, l1092.	2.3	28
149	Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epileptic Disorders, 2019, 21, 319-329.	1.3	28
150	Interlaboratory Variability in the Quantification of New Generation Antiepileptic Drugs Based on External Quality Assessmentâ€ƒData. Epilepsia, 2003, 44, 40-45.	5.1	27
151	Revisiting phenobarbital for epilepsy. BMJ: British Medical Journal, 2004, 329, 1199-1200.	2.3	27
152	The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Research, 2006, 70, 153-160.	1.6	27
153	Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. , 2021, 226, 107866.		27
154	Newer and Older Antidepressants. CNS Drugs, 1994, 2, 479-497.	5.9	26
155	Mechanisms of Tolerance and Drug Resistance. , 0, , 109-118.		26
156	NICE guidance on newer drugs for epilepsy in adults. BMJ: British Medical Journal, 2004, 328, 1273-1274.	2.3	25
157	When clinical trials make history: Demonstrating efficacy of new antiepileptic drugs as monotherapy. Epilepsia, 2010, 51, 1933-1935.	5.1	25
158	Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy. Epilepsia Open, 2016, 1, 9-21.	2.4	25
159	Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines. Epilepsy Currents, 2020, 20, 69-72.	0.8	25
160	Ageâ€Related Changes in Pharmacokinetics: Predictability and Assessment Methods. International Review of Neurobiology, 2007, 81, 183-199.	2.0	24
161	New and forthcoming anti-epileptic drugs. Current Opinion in Neurology, 2011, 24, 159-164.	3.6	24
162	Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. Epilepsy Research, 2011, 94, 117-120.	1.6	24

#	Article	IF	Citations
163	Developing clinical practice guidelines for epilepsy: A report from the ILAE Epilepsy Guidelines Working Group. Epilepsia, 2015, 56, 1859-1869.	5.1	24
164	Off-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy. CNS Drugs, 2014, 28, 939-949.	5.9	23
165	Sertralineâ€induced potentiation of the CYP3A4â€dependent neurotoxicity of carbamazepine: An in vitro study. Epilepsia, 2015, 56, 439-449.	5.1	23
166	Validated outcome of treatment changes according to International League Against Epilepsy criteria in adults with drugâ€resistant focal epilepsy. Epilepsia, 2019, 60, 1114-1123.	5.1	23
167	Introduction to the epilepsy syndrome papers. Epilepsia, 2022, 63, 1330-1332.	5.1	23
168	Current Trends in Antiepileptic Drug Therapy. Epilepsia, 2003, 44, 41-47.	5.1	22
169	Free and Total Serum Concentrations of Carbamazepine and Carbamazepineâ€10, 11â€Epoxide in Infancy and Childhood. Epilepsia, 1985, 26, 320-322.	5.1	21
170	Maternal and fetal outcomes associated with vagus nerve stimulation during pregnancy. Epilepsy Research, 2017, 137, 159-162.	1.6	20
171	Novel study design to assess the efficacy and tolerability of antiseizure medications for focalâ€onset seizures in infants and young children: A consensus document from the regulatory task force and the pediatric commission of the International League against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). Epilepsia Open, 2019, 4, 537-543.	2.4	20
172	Recent advances in the diagnosis and treatment of epilepsy. European Journal of Neurology, 2001, 8, 519-539.	3.3	19
173	The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: A case-control study. Epilepsy Research, 2013, 103, 245-253.	1.6	19
174	Evaluation of drug treatment outcome in epilepsy: a clinical perspective. , 1997, 19, 217-222.		18
175	Prenatal exposure to antiepileptic drugs. Lancet, The, 2006, 367, 1467-1469.	13.7	18
176	Old versus new antiepileptic drugs: the SANAD study. Lancet, The, 2007, 370, 313.	13.7	18
177	A Novel Enantioselective Microassay for the High-Performance Liquid Chromatography Determination of Oxcarbazepine and Its Active Metabolite Monohydroxycarbazepine in Human Plasma. Therapeutic Drug Monitoring, 2007, 29, 319-324.	2.0	17
178	What can we learn from clinical trials of anticonvulsant drugs in epilepsy?. European Journal of Pain, 2002, 6, 35-44.	2.8	16
179	Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 854, 63-67.	2.3	16
180	Commentary: Epilepsy is a Global Problem. Epilepsia, 2014, 55, 1326-1328.	5.1	16

#	Article	IF	Citations
181	Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy. Molecular Neurobiology, 2019, 56, 8392-8407.	4.0	16
182	2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction. Epilepsia, 2019, 60, 1040-1044.	5.1	15
183	Invasive EEG in Presurgical Evaluation of Epilepsy. , 0, , 767-798.		15
184	Optimal choice of antiseizure medication: Agreement among experts and validation of a webâ€based decision support application. Epilepsia, 2021, 62, 220-227.	5.1	13
185	Pediatric adverse reactions to antiseizure medications â€“ An analysis of data from the Italian spontaneous reporting system (2001â€“2019). Epilepsy and Behavior, 2021, 119, 107989.	1.7	13
186	Availability of antiepileptic drugs across Europe. Epilepsia, 2015, 56, e191-7.	5.1	12
187	Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?. Epilepsia, 2019, 60, 175-183.	5.1	12
188	Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review. Epilepsy and Behavior, 2020, 103, 106861.	1.7	12
189	Bioequivalence and switchability of generic antiseizure medications (ASMs): A reâ€appraisal based on analysis of generic ASM products approved in Europe. Epilepsia, 2021, 62, 285-302.	5.1	12
190	In vivo plasma protein binding interaction between valproic acid and naproxen. European Journal of Drug Metabolism and Pharmacokinetics, 1984, 9, 359-363.	1.6	11
191	Seizure-alerting behavior in dogs owned by people experiencing seizures. Epilepsy and Behavior, 2019, 94, 104-111.	1.7	11
192	Antiepileptic drug use and epileptic seizures in nursing home residents in the Province of Pavia, Italy: A reappraisal 12 years after a first survey. Epilepsy Research, 2016, 119, 41-48.	1.6	10
193	The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?. Epileptic Disorders, 2003, 5 Suppl 1, S17-26.	1.3	10
194	Trials in the elderly. Epilepsy Research, 2001, 45, 149-151.	1.6	9
195	Translating monotherapy trials into clinical practice: a look into the abyss. Epilepsy and Behavior, 2003, 4, 457-463.	1.7	9
196	The treatment of the first seizure: The risks. Epilepsia, 2008, 49, 29-34.	5.1	9
197	Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. Epilepsia, 2009, 50, 1891-1898.	5.1	9
198	Antiepileptic Drug Teratogenicity and De Novo Genetic Variation Load. Annals of Neurology, 2020, 87, 897-906.	5.3	9

#	Article	IF	Citations
199	Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?. CNS Drugs, 2022, 36, 113-122.	5.9	9
200	Patient-tailored antiepileptic drug therapy: predicting response to antiepileptic drugs. International Congress Series, 2002, 1244, 93-103.	0.2	8
201	Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*). Trials, 2020, 21, 957.	1.6	8
202	Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements. BMC Neurology, 2021, 21, 410.	1.8	8
203	A webâ€based algorithm to rapidly classify seizures for the purpose of drug selection. Epilepsia, 2021, 62, 2474-2484.	5.1	7
204	Webâ€based decision support system for patientâ€tailored selection of antiseizure medication in adolescents and adults: An external validation study. European Journal of Neurology, 2022, 29, 382-389.	3.3	7
205	Cenobamate: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy. CNS and Neurological Disorders - Drug Targets, 2023, 22, 394-403.	1.4	7
206	Predictability of metabolic antiepileptic drug interactions. , 2005, , 57-92.		6
207	When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy?. Lancet Neurology, The, 2010, 9, 457-459.	10.2	6
208	No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia riskâ€"An analysis of Finnish health register and German health insurance data. Epilepsia, 2018, 59, 1303-1306.	5.1	6
209	Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy. Epilepsia, 2020, 61, e79-e84.	5.1	6
210	Does screening for adverse effects improve health outcomes in epilepsy?. Neurology, 2020, 95, e239-e246.	1.1	6
211	Basal Ganglia Dysmorphism in Patients With Aicardi Syndrome. Neurology, 2021, 96, e1319-e1333.	1.1	6
212	Selection of antiseizure medications for first add-on use: A consensus paper. Epilepsy and Behavior, 2021, 122, 108087.	1.7	6
213	Interpretation of Drug Levels: Relevance of Plasma Protein Binding. Novartis Foundation Symposium, 1980, , 51-68.	1.1	6
214	MRI in the Presurgical Evaluation. , 0, , 805-820.		6
215	The EpiPick algorithm to select appropriate antiseizure medications in patients with epilepsy: Validation studies and updates. Epilepsia, 2022, 63, 254-255.	5.1	6
216	A simple and rapid HPLCâ€UV method for the determination of retigabine in human plasma. Biomedical Chromatography, 2018, 32, e4168.	1.7	5

#	Article	IF	Citations
217	EURAP registry: inadequate monitoring of prescribed drugs in pregnancy â€“ Authors' reply. Lancet Neurology, The, 2018, 17, 741-742.	10.2	5
218	Advocacy for children with epilepsy: Leveraging the <scp>WHA</scp> resolution. Advocacy Task Force, Commission of Pediatrics, International League Against Epilepsy. Epilepsia Open, 2018, 3, 167-174.	2.4	5
219	Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2020, 42, 309-314.	2.0	5
220	Epidemiology and Prognosis of Epilepsy. , 0, , 21-31.		5
221	Benzodiazepines used Primarily for Emergency Treatment (Diazepam, Lorazepam and Midazolam). , 0, , 431-446.		5
222	Rufinamide. , 0, , 647-655.		5
223	Mechanisms of Antiepileptic Drug Action. , 0, , 91-108.		5
224	Psychiatric Features of Epilepsy and their Management. , 0, , 273-287.		5
225	Epilepsy: seizures, syndromes, and survival. Lancet Neurology, The, 2009, 8, 10-12.	10.2	4
226	Management of Side-Effects of Antiepileptic Drugs. , 0, , 289-299.		4
227	General Principles of Medical Management. , 0, , 119-139.		4
228	How long for epilepsy remission in the <scp>ILAE</scp> definition?. Epilepsia, 2017, 58, 1486-1487.	5.1	4
229	Drug interactions with carbamazepine: An ever expanding list?. Epilepsy Research, 2018, 147, 119-120.	1.6	4
230	No Evidence of a Causal Role of Antiepileptic Drug Treatment with Regard to the Development of Dementia. Journal of the American Geriatrics Society, 2018, 66, 1850-1852.	2.6	4
231	Classification as autonomic versus sensory seizures. Epilepsia, 2019, 60, 2003-2005.	5.1	4
232	New paradigms for the treatment of pediatric monogenic epilepsies: Progressing toward precision medicine. Epilepsy and Behavior, 2021, , 107961.	1.7	4
233	Retigabine. , 0, , 637-646.		4
234	Neuropsychological Testing in Presurgical Evaluation. , 0, , 851-863.		4

#	Article	IF	Citations
235	On-Line Solid Phase Extraction High Performance Liquid Chromatography Method Coupled With Tandem Mass Spectrometry for the Therapeutic Monitoring of Cannabidiol and 7-Hydroxy-cannabidiol in Human Serum and Saliva. Frontiers in Pharmacology, 0, 13, .	3.5	4
236	Trial duration and follow-up. Epilepsy Research, 2001, 45, 123-127.	1.6	3
237	Principles of pharmacotherapy of the epilepsies. , 2002, , 1301-1312.		3
238	Active control trials: Endpoints beyond conventional efficacy and tolerability measures. Epilepsy Research, 2006, 68, 73-74.	1.6	3
239	Changes in plasma levetiracetam concentrations in pregnant women and their breastfed infants. Nature Clinical Practice Neurology, 2007, 3, 538-539.	2.5	3
240	Commentary: Why an International Epilepsy Day?. Epilepsia, 2015, 56, 170-171.	5.1	3
241	An investigation of the influence of patientâ€related factors and comedications on lamotrigine clearance in patients with epilepsy. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 685-689.	1.9	3
242	The safety of generic substitution in epilepsy. Lancet Neurology, The, 2016, 15, 344-345.	10.2	3
243	Genetic testing to prevent adverse reactions to antiepileptic drugs. Neurology, 2018, 90, 155-156.	1.1	3
244	A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV). Epilepsy Research, 2019, 153, 66-67.	1.6	3
245	Aetiology of Epilepsy. , 0, , 33-53.		3
246	Experimental Neurophysiological Techniques. , 0, , 829-849.		3
247	Vagal Nerve Stimulation. , 0, , 1017-1023.		3
248	Management of Medical Co-morbidity Associated with Epilepsy. , 0, , 259-272.		3
249	Benzodiazepines used Primarily for Chronic Treatment (Clobazam, Clonazepam, Clorazepate and) Tj ETQq1 1 0.784314 rgBT /Overloc		3
250	Diurnal Fluctuations in Free and Total Plasma Concentrations of Carbamazepine at Steady-State and Correlation with Intermittent Side Effects in Epileptic Patients. Clinical Pharmacokinetics, 1984, 9, 93-94.	3.5	2
251	Pregabalin as Adjunctive Treatment of Partial Seizures. CNS Drugs, 2005, 19, 273-274.	5.9	2
252	Management of Epilepsy in People with Learning Disabilities. , 0, , 219-229.		2

#	Article	IF	Citations
253	Management of Chronic Active Epilepsy in Adults. , 0, , 153-162.		2
254	Management of Childhood Epilepsy Syndromes. , 0, , 179-194.		2
255	The initial impact of the SARSâ€CoVâ€2 pandemic on epilepsy research. Epilepsia Open, 2021, 6, 255-265.	2.4	2
256	Traumatic Brain Injury and Other Risks. , 0, , 249-257.		2
257	Medical Treatment of Epilepsy in Situations with Limited Resources. , 0, , 379-385.		2
258	Adrenocorticotropic Hormone and Corticosteroids. , 0, , 411-419.		2
259	Differential Diagnosis of Epilepsy. , 0, , 55-66.		2
260	Antiepileptic Drug Discovery. , 0, , 81-89.		2
261	Management of Newly Diagnosed Epilepsy. , 0, , 141-151.		2
262	Management of Epilepsies Associated with Specific Diseases in Children. , 0, , 195-201.		2
263	Felbamate. , 0, , 511-518.		2
264	Challenges in the pharmacotherapy of the epilepsies. Expert Review of Neurotherapeutics, 2002, 2, 439-442.	2.8	1
265	Clinical pharmacology and therapeutic use of the new antiepileptic drugs Fundamental and Clinical Pharmacology (2001) 15 405-417. Fundamental and Clinical Pharmacology, 2002, 16, 249-249.	1.9	1
266	Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits?. Nature Clinical Practice Neurology, 2007, 3, 194-195.	2.5	1
267	Reproductive Aspects of Epilepsy Treatment. , 0, , 323-333.		1
268	Management of Epilepsy in Infants. , 0, , 171-178.		1
269	Emergency Treatment of Seizures and Status Epilepticus. , 0, , 231-247.		1
270	A Tribute to Steve White. Neurochemical Research, 2017, 42, 1867-1868.	3.3	1

#	Article	IF	Citations
271	Introduction to the Choice of Antiepileptic Drugs. , 0, , 387-398.		1
272	Management of Epilepsy in Remission. , 0, , 163-169.		1
273	Management of Epilepsy in the Elderly. , 0, , 203-217.		1
274	Ketogenic Diets. , 0, , 301-310.		1
275	Non-pharmacological, Complementary and Alternative Treatments for Epilepsy. , 0, , 311-322.		1
276	Epilepsy Counselling. , 0, , 335-340.		1
277	Genetic Counselling in Epilepsy. , 0, , 341-360.		1
278	Carisbamate. , 0, , 475-484.		1
279	Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. Epileptic Disorders, 2005, 7 Suppl 1, S14-21.	1.3	1
280	Drug interactions in epilepsy. Arquivos De Neuro-Psiquiatria, 1980, 38, 331-340.	0.8	0
281	Trials in women. Epilepsy Research, 2001, 45, 147.	1.6	0
282	Commentary: Message from the ILAE president. Epilepsia Open, 2016, 1, 8-8.	2.4	0
283	Response: Cannabidiol antiseizure activity and its interactions with clobazam: â€œItâ€™s dÃ©jÃ vu all over againâ€•Yogi Berra. Epilepsia, 2020, 61, 1793-1794.	5.1	0
284	A young woman with recurring seizures. Neurosciences, 2011, 16, 292-4.	0.1	0
285	The 50th anniversary of the Italian League Against Epilepsy (Lega Italiana Contro lâ€™Epilessia). Epilepsy and Behavior Reports, 2022, 19, 100553.	1.0	0